Aurinia Pharmaceuticals (STU:IKAP) Net Interest Margin (Bank Only) %


STU:IKAP Aurinia Pharmaceuticals Inc STU:IKAP
78 GF Score
Price €14.15
GF Value €12.23
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:IKAP
78GF Score
Aurinia Pharmaceuticals Inc STU:IKAP
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurinia Pharmaceuticals (STU:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €14.15 is trading 15.7% above its estimated GF Value™ of €12.23. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for STU:IKAP:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €12.23 vs. price of €14.15 (15.7% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the STU:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USA
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
78GF Score

Get the complete analysis for STU:IKAP

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.15
Price
€12.23
GF Value